A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | MicrobiomeTrials← Back to trialsNCT07066657
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2025-07-25Est. Completion: 2028-03
Enrollment target: 572 participants Locations- ULCA, Los Angeles, California, United States
- UCSF, San Francisco, California, United States
- University of Colorado, Aurora, Colorado, United States
- Sarah Cannon Research Institute, Denver, Colorado, United States
- Sarah Cannon Research Institute, Sarasota, Florida, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- NEXT Dallas, Irving, Texas, United States
- NEXT Virginia, Fairfax, Virginia, United States
- Fred Hutchinson Cancer Center, Seattle, Washington, United States
- Peking University Cancer Hospital, Beijing, Beijing Municipality, China
- Beijing Gobroad Hospital, Beijing, Beijing Municipality, China
- Army Medical Center of PLA, Chongqing, Chongqing Municipality, China
- Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Zhejiang, Hangzhou, China
- Harbin Medical University Cancer Hospital, Heilongjiang, Harbin, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
Other microbiome trials you might be interested in
Clinical Stage III Cutaneous Melanoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage IV Cutaneous Melanoma AJCC v8Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Recurrent Head and Neck Squamous Cell CarcinomaLocally Recurrent Hypopharyngeal Squamous Cell CarcinomaLocally Recurrent Laryngeal Squamous Cell CarcinomaLocally Recurrent Oral Cavity Squamous Cell CarcinomaLocally Recurrent Oropharyngeal Squamous Cell CarcinomaMetastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaHunan Cancer Hospital, Changsha, Hunan, ChinaCancer Hospital of Shandong First Medical University, Shandong, Jinan, ChinaRenji Hospital Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality, ChinaZhongshan Hospital Fudan University, Shanghai, Shanghai Municipality, ChinaMetastatic Melanoma
Metastatic Oral Cavity Squamous Cell Carcinoma
Metastatic Oropharyngeal Squamous Cell Carcinoma
Recurrent Melanoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Lip and Oral Cavity Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Stage IV Hypopharyngeal Carcinoma AJCC v8
Stage IV Laryngeal Cancer AJCC v8
Stage IV Lip and Oral Cavity Cancer AJCC v8
Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Unresectable Melanoma
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in tr…
Phoenix, United StatesEst. completion Jan 1, 2027
Cancer Harboring BRAF AlterationsHGGLGGSolid Tumors
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF a…
Beverly Hills, United StatesEst. completion Dec 31, 2027
Solid Tumors Harboring MET Amplification
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this stud…
Beverly Hills, United StatesEst. completion Dec 2030